Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938125 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL5509505 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL13145899 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL3919839 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL7204425 | 0.86 | PTGS2 (0.50) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL14384259 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL3928524 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL5509506 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL7204421 | 0.86 | PTGS2 (0.50) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL1013073 | 0.85 | STAT3 (0.53) | ALDH1A1KMT2AMAPTMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227469-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-08-06 | — | — | US | disclosed |
| US-7534798-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1745034-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005077938-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | ALDH1A1 3238/4885KMT2A 3777/4885MAPT 755/4885 |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALDH1A1 3238/4885KMT2A 3777/4885MAPT 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.